Folger Nolan Fleming Douglas Capital Management Inc. Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Folger Nolan Fleming Douglas Capital Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 8.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 30,101 shares of the biopharmaceutical company’s stock after selling 2,824 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Pfizer were worth $867,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Unique Wealth Strategies LLC purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $1,069,000. Intact Investment Management Inc. increased its position in shares of Pfizer by 30.9% during the fourth quarter. Intact Investment Management Inc. now owns 438,800 shares of the biopharmaceutical company’s stock worth $12,633,000 after purchasing an additional 103,600 shares in the last quarter. Addison Advisors LLC grew its holdings in Pfizer by 11.6% in the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 970 shares in the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter valued at $962,000. Finally, Headlands Technologies LLC purchased a new stake in Pfizer in the 4th quarter valued at $1,184,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Finally, Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Up 0.6 %

PFE traded up $0.14 during mid-day trading on Friday, hitting $25.40. 46,526,457 shares of the stock were exchanged, compared to its average volume of 34,120,812. The firm’s fifty day moving average is $26.96 and its two-hundred day moving average is $28.42. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market cap of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the company earned $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.